Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
暂无分享，去创建一个
Keunchil Park | M. Krzakowski | S. Ramalingam | C. Barrios | R. Rosell | D. Talbot | F. Blackhall | I. Taylor | M. Boyer | I. Bover | S. Letrent | A. Ruiz-Garcia | J. O'Connell | Jane Q. Liang | A. Campbell | R. Frank | Dae Seog Heo